deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02217566

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer, Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Sponsor: Janssen Research & Development, LLC

Conditions Prostatic Neoplasms
Interventions Abiraterone acetate Androgen deprivation therapy (ADT) Prednisone
Updated 14 times since 2017 Last updated: Jan 9, 2020 Started: Sep 23, 2014 Primary completion: Oct 26, 2018 Completion: Oct 26, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02217566, this PHASE2 trial focuses on Prostatic Neoplasms and remains completed. Sponsored by Janssen Research & Development, LLC, it has been updated 14 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2020 · 13 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Jan 2019 — Feb 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations